FAQs: Luxturna (voretigene neparvovec)
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Search
Search results
Our commitment to lived experience employment
In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.
Kathy Evans, Chair of Trustees
Kathy joined Retina UK as Chair of Trustees in September 2024.
Frequently asked questions
These are some of the most commonly asked questions about genetic testing and counselling.
Meet a Researcher: Dr Rachel Taylor
Dr Rachel Taylor is part of the UK Inherited Retinal Dystrophy Consortium (UKIRDC) team at the University of Manchester.
Meet a Researcher: Tomasz Tomkiewicz
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.
Completed Research Project Outcomes
The following projects were being funded by Retina UK and have recently come to an end.
Growth factors
Growth factors are substances that promote the health and function of cells and tissues in the body.
Research brings hope for the future
“All the promising research makes you feel like there is light at the end of that very dark tunnel after all.”
Research round-up, spring 2023
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.